Skip to content

Debt-to-equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×0.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
0.1×-0.2×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
0.0×
Vera Therapeutics logo
Vera TherapeuticsVERA
0.2×0.0×
Immunome logo
ImmunomeIMNM
0.0×

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

Based on the most recent quarter.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's debt-to-equity?
Kodiak Sciences Inc (KOD) reported debt-to-equity of 0.5× in Q1 2026.
How has Kodiak Sciences Inc's debt-to-equity changed year-over-year?
Kodiak Sciences Inc's debt-to-equity decreased by 19.6% year-over-year, from 0.6× to 0.5×.
What is the long-term trend for Kodiak Sciences Inc's debt-to-equity?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's debt-to-equity has grown at a 33.1% compound annual growth rate (CAGR), from 0.1× to 0.4×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.